title: Pharmaceutical Approval Update.
abstract: Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey) for combination HIV-1 therapy; dapsone gel, 7.5% (Aczone) for acne vulgaris; extended-release tofacitinib (Xeljanz XR) for rheumatoid arthritis; and brivaracetam (Briviact) for epilepsy.
authors.forename: Chris
authors.initials: C
authors.lastname: Fellner